{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:36:17Z","timestamp":1785353777696,"version":"3.55.0"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An\u00e4sthesiol Intensivmed Notfallmed Schmerzther"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Vasopressoren kommen besonders in kritischen, nicht selten lebensbedrohlichen Situationen der An\u00e4sthesie, Notfall- und Intensivmedizin zum Einsatz. Die Wahl der geeigneten Substanz sowie die Erkennung und Beherrschung m\u00f6glicher Nebenwirkungen sind von gro\u00dfer Bedeutung. Im folgenden Beitrag sollen daher die klinisch wichtigsten Substanzen vorgestellt und deren pharmakologische Charakteristika beleuchtet werden.<\/jats:p>","DOI":"10.1055\/a-1214-4485","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T22:34:11Z","timestamp":1625006051000},"page":"414-426","source":"Crossref","is-referenced-by-count":2,"title":["Zwanzig Jahre Levosimendan"],"prefix":"10.1055","volume":"56","author":[{"given":"Helene A.","family":"H\u00e4berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2017.9973","article-title":"Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: The LICORN randomized clinical trial","volume":"318","author":"B Cholley","year":"2017","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","article-title":"Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery","volume":"376","author":"R H Mehta","year":"2017","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/jocs.12562","article-title":"Levosimendan reduces mortality in adults with left ventricular dysfunction undergoing cardiac surgery: a systematic review and meta-analysis","volume":"30","author":"J Y Lim","year":"2015","journal-title":"J Card Surg"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial","volume":"297","author":"A Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1074\/jbc.M007484200","article-title":"Binding of levosimendan, a calcium sensitizer, to cardiac troponin C","volume":"276","author":"T Sorsa","year":"2001","journal-title":"J Biol Chem"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/jmcc.1999.1093","article-title":"Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan","volume":"32","author":"J Levijoki","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/s0022-2828(95)91371-8","article-title":"Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension","volume":"27","author":"H Haikala","year":"1995","journal-title":"J Mol Cell Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/0022-2828(95)90009-8","article-title":"Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan","volume":"27","author":"H Haikala","year":"1995","journal-title":"J Mol Cell Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s13054-019-2674-4","article-title":"Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper","volume":"23","author":"B Cholley","year":"2019","journal-title":"Crit Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0014-2999(97)01108-4","article-title":"Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes","volume":"333","author":"H Yokoshiki","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.bcp.2004.05.018","article-title":"Potassium-specific effects of levosimendan on heart mitochondria","volume":"68","author":"D M Kopustinskiene","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/s0735-1097(02)02968-6","article-title":"Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study","volume":"41","author":"G M Felker","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/1074248418763957","article-title":"Cardioprotective and anti-aggregatory effects of levosimendan on isoproterenol-induced myocardial injury in high-fat-fed rats involves modulation of PI3K\/Akt\/mTOR signaling pathway and inhibition of apoptosis: comparison to cilostazol","volume":"23","author":"M K Tawfik","year":"2018","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/sj.bjp.0707157","article-title":"Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl\/Rapp rats","volume":"150","author":"M Louhelainen","year":"2007","journal-title":"Br J Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10557-005-5417-5","article-title":"Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure","volume":"19","author":"D N Tziakas","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"J Comin-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/ejhf.118","article-title":"Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial","volume":"16","author":"J Altenberger","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1053\/j.jvca.2019.10.017","article-title":"Adrenergic downregulation in critical care: molecular mechanisms and therapeutic evidence","volume":"34","author":"A Belletti","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/eurjhf\/hfn045","article-title":"Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE","volume":"11","author":"A Mebazaa","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/eurjhf\/hfq032","article-title":"Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers","volume":"12","author":"C H Bergh","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1053\/j.jvca.2018.04.019","article-title":"Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery \u2013 a retrospective before-and-after study","volume":"32","author":"A Jacky","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/bja\/aew151","article-title":"Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery","volume":"117","author":"K Distelmaier","year":"2016","journal-title":"Br J Anaesth"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2045893217743122","DOI":"10.1177\/2045893217743122","article-title":"Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure","volume":"8","author":"M S Hansen","year":"2018","journal-title":"Pulm Circ"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lfs.2017.07.001","article-title":"Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis","volume":"184","author":"J Qiu","year":"2017","journal-title":"Life Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.medin.2017.08.009","article-title":"Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis","volume":"42","author":"M Fang","year":"2018","journal-title":"Med Intensiva"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1616325","article-title":"Levosimendan for hemodynamic support after cardiac surgery","volume":"376","author":"G Landoni","year":"2017","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s00134-019-05731-w","article-title":"Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial","volume":"45","author":"D B Antcliffe","year":"2019","journal-title":"Intensive Care Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/s0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"F Follath","year":"2002","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","article-title":"Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"V S Moiseyev","year":"2002","journal-title":"Eur Heart J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"M Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ehf2.12366","article-title":"Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period","volume":"6","author":"G Polzl","year":"2019","journal-title":"ESC Heart Fail"}],"container-title":["AINS - An\u00e4sthesiologie \u00b7 Intensivmedizin \u00b7 Notfallmedizin \u00b7 Schmerztherapie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1214-4485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T22:34:20Z","timestamp":1625006060000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1214-4485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":31,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2021,6,29]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1214-4485","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0939-2661","1439-1074"],"issn-type":[{"value":"0939-2661","type":"print"},{"value":"1439-1074","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}